Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Pitolisant Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    HARMONY BIOSCIENCES Acknowledges FDA Action on WAKIX® Citizen Petition
    HARMONY BIOSCIENCES Acknowledges FDA Action on WAKIX® Citizen Petition

    25 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harmony-biosciences-acknowledges-us-food--drug-administration-fda-action-denying-the-citizen-petition-for-wakix-pitolsiant-302181609.html

    PR NEWSWIRE
    25 Jun 2024
    Share Share
    Harmony Receives FDA Approval For WAKIX® (Pitolisant) In Pediatric Narcolepsy
    Harmony Receives FDA Approval For WAKIX® (Pitolisant) In Pediatric Narcolepsy

    24 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harmony-biosciences-receives-us-food-and-drug-administration-approval-for-wakix-pitolisant-in-pediatric-patients-with-narcolepsy-302179754.html

    PR NEWSWIRE
    24 Jun 2024
    Share Share
    Harmony Bio Initiates Ph 3 of Pitolisant in Patients with Prader-Willi Syndrome
    Harmony Bio Initiates Ph 3 of Pitolisant in Patients with Prader-Willi Syndrome

    03 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harmony-biosciences-initiates-global-phase-3-registrational-trial-tempo-study-of-pitolisant-in-patients-with-prader-willi-syndrome-302106423.html

    PR NEWSWIRE
    03 Apr 2024
    Share Share
    Harmony Biosciences Receives FDA Orphan Drug Designation For Pitolisant
    Harmony Biosciences Receives FDA Orphan Drug Designation For Pitolisant

    20 Feb 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harmony-biosciences-receives-us-food-and-drug-administration-orphan-drug-designation-for-pitolisant-in-prader-willi-syndrome-302065480.html

    PR NEWSWIRE
    20 Feb 2024
    Share Share
    Harmony Announces Positive Data From Phase 2 Study Evaluating Pitolisant
    Harmony Announces Positive Data From Phase 2 Study Evaluating Pitolisant

    07 Dec 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/harmony-biosciences-announces-positive-topline-data-from-phase-2-signal-detection-study-evaluating-pitolisant-in-adult-patients-with-myotonic-dystrophy-type-1-302008352.html

    PR NEWSWIRE
    07 Dec 2023
    Share Share
    FDA Confirms Paragraph IV Patent Litigation for Pitolisant Hydrochloride Tablets
    FDA Confirms Paragraph IV Patent Litigation for Pitolisant Hydrochloride Tablets

    31 Oct 2023

    // FDA

    https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-pitolisant-hydrochloride-tablets-47857.pdf

    FDA
    31 Oct 2023
    Share Share